ClinicalTrials.gg
RecruitingNCT07567131stEPPUpdated May 5, 2026

Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP)

An observational study in Erythropoietic Protoporphyria (EPP) and X-Linked Porphyria (XLP), sponsored by Portal Therapeutics, Inc.. Recruiting at 19 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Portal Therapeutics, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Protoporphyria, Erythropoietic with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Protoporphyria, Erythropoietic · United States.

Started
2026
with 1 other
Observational
4 of 18
2 open now
Registered
16th of 18
by date
Lead sponsor
3 of 18
Portal Therapeutics, Inc.

Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, this one is one of 2 that started in 2026, is one of 4 observational ones, and was the 16th registered.

Protoporphyria, Erythropoietic

29 studies on the registry are indexed under Protoporphyria, Erythropoietic; 5 are open to participants now.

Browse Protoporphyria, Erythropoietic studies →

Open to participants now

4 of the 18 studies in Protoporphyria, Erythropoietic with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Protoporphyria, Erythropoietic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Protoporphyria, Erythropoietic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to collect information about the effects of EPP/XLP in adults and adolescents. This is an observational study in which participants will not receive any treatment. Study details include:

  • The study duration will be up to 6 months for each participant.
  • After Screening, participants will have a Baseline (Day 1) visit and return for visits every 4 weeks through 24 weeks.
  • Assessments to evaluate EPP/XLP will include clinical laboratory tests, physical exams, vital signs measurement, blood draws for PPIX concentration, reporting of EPP/XLP-related symptoms (including completion of a daily diary), light dosimetry.
03

Conditions studied

  • Erythropoietic Protoporphyria (EPP)
  • X-Linked Porphyria (XLP)

Keywords

  • EPP
  • XLP
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study design and key inclusion criteria are focused on EPP/XLP and are inclusive of all potential participants, including those from underrepresented racial and ethnic populations. The sites and countries selected have diverse populations and the potential to enroll diverse participants.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 12 years and older.
  2. Confirmed diagnosis of EPP or XLP as follows:

    1. Genetic confirmation of EPP (FECH mutation with reduced ferrochelatase activity) OR
    2. Genetic confirmation of XLP (ALAS2 gain-of-function mutation) OR
    3. Elevated free PPIX levels in RBCs consistent with EPP/XLP, supported by clinical and/or family history.
  3. Currently has symptoms of EPP/XLP.
  4. History of consistent, non-painful prodrome within approximately 45 minutes of sunlight exposure and prior to phototoxic attacks, as self-reported by the participant.
  5. Willing and able to wear a light dosimetry device during the study.
  6. Willing and able to complete a daily diary of EPP/XLP symptoms.
  7. Willing and able to keep skin sites chosen for provocative sunlight exposure testing covered by opaque material when outside or exposed to potentially triggering light beginning 2 days prior to testing.
  8. Willing and able to provide and/or assent for the study.
  9. Study participants and LAR (as appropriate) are willing and able to comply with study visits and study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of another porphyria or another photodermatosis that may confound the characterization of EPP/XLP.
  2. Has a disease or condition that, at the discretion of the Investigator or Sponsor, would interfere with the evaluation of EPP/XLP or study participation, or would make study participation not in the best interest of the participant.
  3. Is taking, or has taken within 60 days of Day 1, any medication, vitamin, or supplement that alters sensitivity to light exposure (eg, afamelanotide, melanotan, beta carotene, dersimelagon, or bitopertin).
  4. Concurrent or anticipated participation in an interventional clinical trial during the study period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Plasma Protoporphyrin IX (PPIX) Levels Over Time

    Plasma protoporphyrin IX (PPIX) concentrations measured at specified study visits.

    Time frame: Screening; Baseline; Weeks 4, 8, 12, 16, 20, 24

  2. Clinical History of Phototoxic Symptoms and Prodrome Timing

    Medical history of EPP/XLP symptoms, including time to onset of prodromal sensations and occurrence of phototoxic reactions.

    Time frame: Screening, Baseline, Weeks 4, 8, 12, 16, 20, 24

  3. Skin Damage Manifestations

    Skin damage manifestations associated with EPP/XLP, including swelling, erythema, and chronic skin changes.

    Time frame: Screening, Baseline, Weeks 4, 8, 12, 16, 20, 24

  4. Light Exposure and Phototoxic Reaction Data From Daily Diary

    Daily recorded light exposure (including time spent outdoors), light dosimetry measurements, and occurrence of phototoxic reactions as captured in participant diaries.

    Time frame: Screening, Baseline, Weeks 4, 8, 12, 16, 20, 24

  5. Sunlight Exposure Required to Induce Prodromal Symptoms

    Amount of sunlight exposure associated with onset of prodromal symptoms, along with corresponding plasma protoporphyrin IX (PPIX) levels.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20

Secondary outcomes

  1. Liver Function Test Results

    Blood levels of liver function parameters (e.g., alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], bilirubin) and corresponding plasma protoporphyrin IX (PPIX) levels.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24

07

Study locations

9 of 19 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — What may be shared: De-identified individual participant data (no direct identifiers) Who can access it: Qualified researchers with a scientifically sound research proposal Conditions for access: Submission and approval of a research proposal Execution of a data sharing agreement (DSA) Compliance with privacy regulations (e.g., GDPR, HIPAA as applicable) How it will be shared: Through a secure data access process managed by the sponsor or designated data-sharing platform Timing: Typically after study completion and/or publication of primary results Purpose: To support further research on EPP and XLP while protecting participant confidentiality

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Mar 2027, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
May 5, 2026
StartEst.
Apr 30, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Apr 1, 2027
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07567131
Lead sponsor
Portal Therapeutics, Inc.
Responsible party
Sponsor
First posted
May 5, 2026
Start date
Apr 30, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
May 5, 2026

Study contacts

GondolaBio Inquiries
Contact
patientadvocacy@gondolabio.com
650-249-2108 ext. 2178

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion